Development of a mechanistic model to predict synthetic biotic activity in healthy volunteers and patients with phenylketonuria

Abstract

Mark Charbonneau et al. develop a mathematical model that describes the behavior of an engineered bacterial therapeutic, SYNB1618, in the human gastrointestinal tract and its effects on plasma phenylalanine (Phe) levels. This model enables the authors to predict plasma Phe lowering by SYNB1618 in patients with phenylketonuria.